VIDEO NOW AVAILABLE: Oncopeptides hosted Capital Markets Update November 13

Oncopeptides hosted a Capital Markets Update on November 13, 2025, it was broadcasted live and recorded from Inderes studio in Stockholm.

The event provided shareholders and investors with a deeper understanding of the company’s strategic direction, growth plans, and expanding role in the evolving treatment landscape for multiple myeloma.

The half-day program featured presentations and discussions with leading international experts from Europe, Japan, and the U.S., offering clinical, scientific, and market perspectives. Confirmed speakers include:

  • Prof. Dr. Sebastian Theurich, LMU University Hospital Munich
  • Dr. María-Victoria Mateos, University of Salamanca
  • Dr. Claudio Cerchione, IRST IRCCS, Italy
  • Prof. Dr. med. Klaus Fenchel, Germany
  • Prof. Shinsuke Iida, Nagoya City University, Japan
  • Prof. Paul G. Richardson, Dana-Farber Cancer Institute / Harvard Medical School, U.S.

The event will also feature Dr. Björn Odlander, Founder & Managing Partner of HealthCap, and Sofia Heigis, CEO of Oncopeptides, who will share insights on the company’s business outlook and investment case.

 

Download the slides from the event:

Oncopeptides Slides CMU November 13, 2025

 

Watch the livestream below:

The event was held in English and a recording is now available on-demand below. To see the full agenda, please scroll further down. You can also choose different chapters in the video built after the agenda.

 

Full agenda

The event was held in English. All times in CET. Agenda subject to change.

09.00 – 09.03 | Welcome
Speaker: David Augustsson, Director of IR, Oncopeptides.

09.03-09.20 | Bringing Hope through Science
Speaker: Sofia Heigis, CEO, Oncopeptides.

09.20-09.30 | Owner’s perspective
Speaker: Dr. Björn Odlander, founder and managing partner, HealthCap.

09.30-9.55 | Keynote 1: Multiple myeloma and the unmet medical need
Speaker: Prof. Dr. Sebastian Theurich.
Description: An introduction to multiple myeloma and the treatment landscape, emphasizing the need for new treatments in the 4L+ stage.

9.55-10.00 | From Need to Treatment – A Clinician’s Reflection
Speaker: Dr. María‑Victoria Mateos.
Description: Dr. Mateos shares her perspective on the evolving treatment landscape and the clinical relevance of Pepaxti in addressing unmet needs in relapsed and refractory multiple myeloma.

10.00-10.25 | Conversation: Relapsed, refractory multiple myeloma – clinical experience with Pepaxti
Speakers: Dr. Claudio Cerchione, Prof. Dr. med. Klaus Fenchel.
Description: A conversation on the European multiple myeloma landscape and the treatment challenges facing today´s healthcare practitioners.

10.25-10.35 | BREAK

10.35-10.45 | Keynote 2: The Japanese Multiple Myeloma landscape
Speaker: Prof. Shinsuke Iida.

10.45-10.55 | Keynote 3: The potential of the PDC platform in the U.S.
Speaker: Prof. Paul Richardson.

10.55-11.30 | Oncopeptides as an investment case – where do we go from here?
Speaker: Sofia Heigis, CEO, Oncopeptides.

11.30-11.45 | Questions and Answers from investors
All in-person participants.

11.45-11.50 | Closing remarks
Speaker: Sofia Heigis, CEO, Oncopeptides.